Treatment of Streptococcus pneumoniae Meningitis with Third-Generation Cephalosporin Resistance (MIC ≥2 μg/mL)

Standard cephalosporin therapy is insufficient when Streptococcus pneumoniae — the causative organism in this form of bacterial meningitis — has a third-generation cephalosporin minimum inhibitory concentration of 2 μg/mL or higher. This resistance threshold defines a distinct clinical situation that requires a different treatment strategy.

Clinical Scenario

Streptococcal meningitis caused by Streptococcus pneumoniae, confirmed or suspected, where susceptibility testing yields a third-generation cephalosporin MIC of 2 μg/mL or above — indicating that standard cephalosporin concentrations are no longer adequate to suppress the organism.

Treatment Approach

Management of this scenario calls for combination antibiotic therapy — two or more agents used together rather than a single drug — with specific agent selection guided by the resistance profile. An adjunctive agent is added at the outset, beginning with the first dose of antibiotics.

Full regimen — agent selection, targets, alternatives, and duration — is in the structured protocol below.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1016/j.cmi.2016.01.007

Streptococcus pneumoniae

Cephalosporin resistant (MIC 2 μg/mL)

Vancomycin plus rifampicin, or vancomycin plus ceftriaxone or cefotaxime, or rifampicin plus ceftriaxone or cefotaxime

Empiric treatment with dexamethasone is strongly recommended for all adults (10 mg qid for 4 days) and children (0.15 mg/kg qid for 4 days) with acute bacterial meningitis in the setting of high-income countries.

Treatment with dexamethasone is strongly recommended to be initiated with the first dose of antibiotic treatment.

View source ↗